Compare First Citizens BancShares Inc (FCNCA) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Citizens BancShares Inc vs Illumina, Inc. — how do they compare? First Citizens BancShares Inc trades at $2,170.41 (market cap $23.76B), while Illumina, Inc. trades at $189.05 (market cap $28.32B). The key difference: Illumina, Inc. is the larger of the two by market cap, and First Citizens BancShares Inc pays a 0.41% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| FCNCA | ILMN | |
|---|---|---|
Market Cap | $23.76B | $28.32B |
Sector | Sector/Thematic | Health |
52-Week High | $2.20K | $194.33 |
52-Week Low | $1.64K | $91.00 |
Dividend Yield | 0.41% | — |
Enterprise Value | — | $29.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Citizens BancShares (FCNCA) trades at $2,166.64, up 5.06% today, with a neutral technical signal and bullish moving averages. The company reported strong Q1 2026 earnings of $44.86 per share, beating estimates, and maintains a solid net income margin of 24.35%. Recent news includes a planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.
Outlook remains stable with consistent revenue near $9.3B and profit growth. Risks include margin pressure and credit trends, but analyst consensus is a $2,320 price target with a hold-heavy rating. The stock presents a value opportunity with a low P/E of 11.94, though investor sentiment is cautious amid sector challenges.
Illumina (ILMN) trades at $188.27, down 1.53% on the day, yet maintains a strong technical and fundamental posture. The stock is in a bullish trend, supported by consistent earnings beats, robust profitability margins, and positive analyst sentiment. Recent news highlights strong momentum in 2026, driven by sequencing demand and new product launches, positioning the company for growth despite competitive pressures.
The outlook for ILMN is positive, with earnings growth and market leadership in genomics offering upside potential. Key risks include intensifying competition from new entrants like Roche and execution challenges in a dynamic healthcare landscape. Investor sentiment remains buoyant, but vigilance on competitive threats and margin sustainability is warranted for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
